Corresponding author: Mahmoud S. Abu-Samak ( m_abusamak@asu.edu.jo ) Academic editor: Georgi Momekov
© 2021 Mahmoud S. Abu-Samak, Luai Z. Hasoun, Abeer Barham, Beisan A. Mohammad, Ibrahim Mosleh, Ahmad Aljaberi, Shady H. Awwad.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Abu-Samak MS, Hasoun LZ, Barham A, Mohammad BA, Mosleh I, Aljaberi A, Awwad SH (2021) The supplementary effects of omega-3 fatty acid alone and in a combination with vitamin D3 on serum leptin levels: A randomized clinical trial on men and women with vitamin D deficiency. Pharmacia 68(3): 517-525. https://doi.org/10.3897/pharmacia.68.e64422
|
Purpose: This randomized clinical trial (RCT) was designed to assess the effect of VD3, n-3FA, and their combination on serum leptin levels in people with vitamin D deficiency (VDD).
Subjects and methods: One hundred and forty six participants, were randomly assigned into four groups supplemented with the dose of 50,000 IU VD3 taken weekly (D), 300 mg n-3FA taken daily (Om), and their combination (D+Om) or control (C) for eight weeks. Fasting baseline and follow-up (10 weeks; 8 weeks supplementation plus washout period of 2 weeks) of serum 25 hydroxyvitamin D (25OHD), leptin, glucose, triglycerides (TG), parathyroid hormone (PTH), calcium, and phosphorus were assayed. A paired T-test was used to assess the changes in serum leptin levels over of the follow-up period.
Results: Significant increase in follow-up serum leptin (10.62 ± 7.18 to 14.42 ± 8.29 ng/mL, P = 0.002) and TG (154 ± 84.4 to 200.1 ± 79, P = 0.015) levels were observed in n-3-FA supplemented group. Combination therapy (VD3 plus n-3 FA) significantly increased serum 25OHD (13.49 ± 4.64 to 37.09 ± 11.13 ng/mL, P < 0.001), TG levels (114.3 ± 57.3 to 139.1 ± 60.7 mg/mL, P = 0.007) and insignificantly serum leptin (6.74 ± 4.87 to 8.01 ± 6.77 ng/mL, P = 0.269).
Conclusion: Our study referred that notable elevation in leptin and TG levels might be linked to leptin resistance. However, further RCTs are required to clarify possible consequences resulted from the extensive administration of n-3FA supplements and their combinations with high doses of VD3 supplements on humans’ health.
leptin, n-3FA, omega, vitamin D3, diabetes
Vitamin D deficiency (VDD), obesity, and diabetes mellitus (DM) are worldwide problems. There has been growing interest in the association of type 2 DM (T2DM) with VDD to obesity (S
According to
On the other hand, conflicting data obtained from RCTs showed that there are no (
Conversely, a recent RCT (
The current randomized clinical trial (RCT) was authorized by the Institutional Review Board (IRB) committee of Applied Science Private University (ASU) (protocol no. DRGS-4-2018-1) and conducted during the winter season, between December 2018 and March 2019. The RCT was performed according to the declaration of Helsinki. The informed consent was filled from each enrolled participant in this clinical trial. Participants were Jordanian men and women from the ASU community in addition to ASU employees’ relatives with an average age at baseline of the trial was 36.18±9.74 years (range 25 to 55). Eligible participants were enrolled based on a confirmed diagnosis of 25OHD levels deficiency (VDD) by internal medicine consultants in Ibn Al-Haytham hospital laboratories. People previously diagnosed with chronic diseases such as kidney problems were excluded due to the association between prolonged administration of VD3 and kidney stone formation (
The baseline and follow-up measurements of the anthropometric and clinical variables were recorded before and after VD3 and n-3FA supplementation. At the end of the interventional protocol which is 8 weeks, the participants entered a washout period of 2 weeks. Then, follow-up measurements were collected for all the participants. A computer-generated randomization was created by an independent statistician. Eligible participants (n = 188) were allocated into four groups as illustrated in the consort chart (Figure
This RCT was conducted at Pharmacy school laboratories/ ASU during the winter of 2018 where the timing of blood sampling is important to minimize seasonal fluctuations of total levels of vitamin D in the blood (
Clinical parameters assays: After collection, into labeled Eppendorf tubes, serum measurement of clinical parameters was done at the clinical laboratories of Ibn Al-Haytham hospital Amman, Jordan. Vitamin D: Chemiluminescence immunoassay LIAISON 25-hydroxyvitamin D Assay (DiaSorin) was used to measure a total serum concentration of vitamin D (25OHD). The lower limit of assay approximately was (4 ng/mL) with a 100% cross-reactivity with both metabolites of 25OHD, 25OHD2, and 25OHD3 and thus measures total serum 25OHD content. Leptin: Serum levels of leptin were assayed using the enzyme Immunoassay kit (leptin EIA -5302, DRG Diagnostics, Marburg, Germany). Assay Analytical sensitivity was 0.1 ng/mL. Parathyroid Hormone: Serum levels of parathyroid hormone (PTH) were assayed using the enzyme Immunoassay kit (PTH Intact EIA -3645, DRG Diagnostics, Marburg, Germany). The assay analytical sensitivity of the test was 1.57 pg/mL. Calcium and Phosphorus: Calcium and phosphorus (PO4) concentrations in serum were assayed by spectrophotometry method (Clinical Chemistry RAL Analyzers Clima Plus, Spain) using (CALCIUM-ARSENAZO kit (M11570i-15) and Phosphorus Phosphomolybdate/Uv Kit (M11508i-18, BioSystems, Spain). Glucose and Triglycerides: Serum fasting blood glucose (FBG) and triglyceride (TG) levels were assayed on a Roche Cobas C501 analyzer (GLUC3 application, Roche, Mannheim, Germany) using enzymatic colorimetric method. Serum TG levels were measured using TG -BioSystems kits (M11528i-20, BioSystems, Barcelona, Spain). Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) were measured using specific ALT and AST BioSystems kits (M21533i-03, M11531i-23, Barcelona, Spain). Serum creatinine (Cr) and urea levels were measured using Creatinine kit (M12502i-19) and Urea (M11536i-17) kit, BioSystems, Barcelona, Spain) with detection limits = 0.04 mg/dL and 1.3 mg/dL respectively.
The parameter changes at the follow-up period (10 weeks) within each group were assessed by paired Student’s t-test. To investigate if there is any significant difference in the mean values for each parameter between the different groups of trial One Way ANOVA test was used. Post hoc comparisons using the Tukey HSD test were conducted to provide specific analysis on which means are significantly different from each other in the four trial groups, differences were considered significant at P < 0.05. To determine potential factors that influenced leptin at the baseline-end of the trial, multiple linear regression was applied using the stepwise method according to the different groups. Kolmogorov–Smirnov test was used to evaluate the normal distribution of study parameters. Data was approximately close to the normal distribution because of the large sample size of the trial. These statistical analyses were performed using SPSS a Statistical Package for the Social Sciences.
The consort diagram (Figure
The mean age of all participants at baseline of the trial was 36.18 ± 9.74 years (Table
Baseline Descriptive Statistics of the Anthropometric Parameters (n = 146).
Anthropometric Parameter | Mean ±SD | Range |
---|---|---|
Age (year) | 36.18±9.74 | 25.00-55.00 |
Weight (kg) | 77.47±16.11 | 42.00-128.00 |
Height (cm) | 166.33±7.93 | 148.00-187.00 |
BMI (kg.m-2) | 27.57±5.38 | 14.48-50.08 |
Waist (cm) | 92.01±14.57 | 46.00-139.00 |
Hip (cm) | 106.77±12.56 | 43.00-158.00 |
Clinical parameter | Mean ± SD | Range | Normal ranges |
---|---|---|---|
25OHD (ng/mL) | 16.43±7.34 | 3.80-28.2 | 30-50 |
FBG (mg/dL) | 84.88±17.79 | 67.10-115.20 | 70-110 |
Leptin (ng/mL) | 8.78±6.44 | 1.10-31.70 | *NA |
TG (mg/dL) | 129.61±67.12 | 26.30-401.50 | Up to 150 |
PTH (pg/mL) | 33.56±10.95 | 9.26-50.00 | 9-90 |
Calcium (mg/dL) | 9.86±1.78 | 8.50-18.60 | 8.6-10.3 |
PO4 (mg/dL) | 4.12±0.27 | 3.30-5.10 | 2.5-4.5 |
Cr (mg/dL) | 0.90±0.07 | 0.50-1.20 | 0.5-1.1 |
ALT (U/L) | 9.36±3.43 | 0.90-33.00 | Up to 65 |
AST (U/L) | 7.29±1.72 | 3.00-18.00 | Up to 30 |
Urea (mmol/L) | 3.03±0.73 | 0.90-7.50 | 2.5 to 7.1 |
A significant negative correlation between 25OHD and leptin levels was observed in people with VDD at the baseline of the trial (R = –0.257, P = 0.002). A negative correlation but insignificant was also observed between 25OHD levels and BMI values as shown in Table
Correlation of selected obesity variables with 25OHD levels at baseline and follow-up.
Obesity variable | Baseline | Follow up | ||
---|---|---|---|---|
R | P-value | R | P-value | |
BMI (kg.m-2) | -0.153 | 0.066 | *-0.032 | 0.705 |
Weight (kg) | -0.003 | 0.975 | **0.112 | 0.179 |
Waist (cm) | -0.062 | 0.458 | 0.072 | 0.391 |
Leptin (ng/mL) | -0.257 | 0.002 | -0.078 | 0.347 |
WHR | 0.119 | 0.154 | -0.088 | 0.291 |
At the end of the trial, significant differences were observed between the baseline and follow-up mean serum 25OHD levels in the three intervention groups (P-value < 0.01) as shown in Table
Fasting serum 25OHD (ng/mL) | |||||
---|---|---|---|---|---|
Group | C | D | Om | D+Om | P-value |
Baseline | 18.34 ± 7.2 | 17.42 ± 5.7 | 19.7 ± 6.03 | 16.95 ± 4.8 | PB = 0.1 |
Follow-up | 17.7 ± 6.5 | 38.4 ± 13.4 | 12.34 ± 5.9 | 39.7 ± 11.8 | PC < 0.001 |
Change | 0.65 | -20.95 | 7.38 | -22.75 | |
PA | 0.26 | < 0.01 | < 0.01 | < 0.01 |
Exceptionally, only the Om group (Table
Serum leptin ng/ml | |||||
---|---|---|---|---|---|
Group C D Om D+Om P- value | |||||
Baseline | 10.11±8.5 | 8.54±5.1 | 10.62±7.2 | 7.74±4.9 | P B= 0.083 |
Follow-up | 11.49 ±10.3 | 10.26±7.6 | 14.42±8.3 | 8.01±6.8 | P C= 0.005 |
Change | -1.38 | -1.72 | -3.81 | -0.27 | |
P A | 0.501 | 0.083 | 0.002 | 0.269 |
In the current RCT, compared to baseline levels, no significant changes were noted in serum PTH and calcium at follow-up. In turn, except for the C group, phosphorus levels showed notable changes in all study groups with a significant decrease in the means of serum phosphorus (Suppl. material
The mean serum TG levels were significantly increased in both Om and D+Om groups (P-value = 0.015, 0.007, respectively) as shown in Table
The multivariate stepwise regression analysis showed that the predictors at the period of follow-up, that are included in the model together explained ~50%, 33%, 13%, and 49% of the variance in leptin levels in the C, D, Om, and D+Om study groups, respectively (Table
The Multivariate Association between the Trial Variables and Serum Levels of Leptin Using Stepwise Regression at the period of the follow-up.
Dependent variable | Study group | Univariate effect estimates | Coefficient | |||
---|---|---|---|---|---|---|
B | F | R | R2 | |||
Leptin (ng/mL) | C | Calcium (mg/dL) | **3.157 | 14.245 | 0.610 | 0.372 |
ALT (U/L) | 1.741 | 11.510 | 0.707 | 0.500 | ||
D | Paternal DM | *-5.433 | 10.712 | 0.484 | 0.234 | |
Weight (kg) | -0.125 | 8.312 | 0.573 | 0.328 | ||
Om | AST (U/L) | 1.677 | 5.088 | 0.356 | 0.127 | |
D+Om | Calcium (mg/dL) | 1.434 | 12.476 | 0.470 | 0.221 | |
PTH (pg/mL) | 0.123 | 10.295 | 0.569 | 0.324 | ||
Height (cm) | -0.199 | 8.989 | 0.625 | 0.391 | ||
Gender | -3.841 | 8.55 | 0.674 | 0.455 | ||
Sun-exposure | 0.229 | 15.336 | 0.685 | 0.469 | ||
HtWt R (cm/Kg) | 0.005 | 13.510 | 0.701 | 0.491 |
This novel clinical trial on people with VDD indicated that 300 mg daily for 8 weeks of n-3FA significantly raised serum leptin levels concurrently with the decrease of the 25OHD levels. Our observations are in agreement with previous RCTs (
Insulin resistance often associates with exhausted pancreatic beta cells due to prolonged insulin hypersecretion because of poor glycemic control in diabetics or prolonged hyperglycemic levels in pre-diabetics (Al-Shoumer et al. 2015). Insulin hypersecretion subsequently down-regulates insulin receptors causing the development of IR in obese subjects (
This novel RCT provides that eight weeks of n-3FA therapy significantly declined 25OHD levels which were accompanied by a significant increase in leptin and TG levels. Although the combined effect of VD3 plus n-3FA, at follow-up, normalized 25OHD levels, notable elevation in TG, and leptin levels were seen. Accordingly, the intervention of VD3, n-3FA, or their combination may be accompanied by negative effects on leptin resistance. Further clinical trials are required to clarify possible consequences resulted from the co-supplementation of VD3 and omega on humans’ health.
The authors are grateful to the Applied Science Private University (ASU), Amman, Jordan, for the full financial support granted for this research.